Chimeric antigen receptor
US-2024301088-A1 · Sep 12, 2024 · US
Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
US2017190785A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017190785-A1 |
| Application number | US-201715462758-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 17, 2017 |
| Priority date | Dec 8, 2005 |
| Publication date | Jul 6, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
First claim
Opening claim text (preview).
We claim: 1 . An isolated monoclonal antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region derived from a human V H 3-48 gene, wherein the antibody specifically binds to Fucosyl-GM1. 2 . An isolated monoclonal antibody, or an antigen-binding portion thereof, comprising a light chain variable region derived from a human V K L5 gene, wherein the antibody specifically binds to Fucosyl-GM1. 3 . The isolated monoclonal antibody or an antigen-binding portion thereof of claim 1 further comprising a heavy chain variable region derived from a human V H 3-48 gene. 4 . The antibody of claim 1 , comprising: (a) a heavy chain variable region CDR1 comprising SEQ ID NO:13; (b) a heavy chain variable region CDR2 comprising SEQ ID NO:19; (c) a heavy chain variable region CDR3 comprising SEQ ID NO:25; (d) a light chain variable region CDR1 comprising SEQ ID NO:31; (e) a light chain variable region CDR2 comprising SEQ ID NO:37; and (f) a light chain variable region CDR3 comprising SEQ ID NO:43. 5 . The antibody of claim 1 , comprising: (a) a heavy chain variable region CDR1 comprising SEQ ID NO:14; (b) a heavy chain variable region CDR2 comprising SEQ ID NO:20; (c) a heavy chain variable region CDR3 comprising SEQ ID NO:26; (d) a light chain variable region CDR1 comprising SEQ ID NO:32; (e) a light chain variable region CDR2 comprising SEQ ID NO:38; and (f) a light chain variable region CDR3 comprising SEQ ID NO:44.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
comprising antibodies · CPC title
from primates, e.g. man · CPC title
Internalization into the cell · CPC title
Complementarity determining region [CDR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017190785A1 cover?
- The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutica…
- Who is the assignee on this patent?
- Squibb & Sons Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/3084. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jul 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).